155 related articles for article (PubMed ID: 35169089)
21. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.
Jenseit A; Camgöz A; Pfister SM; Kool M
Acta Neuropathol; 2022 Jan; 143(1):1-13. PubMed ID: 34762160
[TBL] [Abstract][Full Text] [Related]
22. cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors.
Ellison DW; Aldape KD; Capper D; Fouladi M; Gilbert MR; Gilbertson RJ; Hawkins C; Merchant TE; Pajtler K; Venneti S; Louis DN
Brain Pathol; 2020 Sep; 30(5):863-866. PubMed ID: 32502305
[TBL] [Abstract][Full Text] [Related]
23. C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma.
Cachia D; Wani K; Penas-Prado M; Olar A; McCutcheon IE; Benjamin RS; Armstrong TS; Gilbert MR; Aldape KD
Brain Tumor Pathol; 2015 Apr; 32(2):105-11. PubMed ID: 25388523
[TBL] [Abstract][Full Text] [Related]
24. Updates in the classification of ependymal neoplasms: The 2021 WHO Classification and beyond.
Kresbach C; Neyazi S; Schüller U
Brain Pathol; 2022 Jul; 32(4):e13068. PubMed ID: 35307892
[TBL] [Abstract][Full Text] [Related]
25. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
Pajtler KW; Wen J; Sill M; Lin T; Orisme W; Tang B; Hübner JM; Ramaswamy V; Jia S; Dalton JD; Haupfear K; Rogers HA; Punchihewa C; Lee R; Easton J; Wu G; Ritzmann TA; Chapman R; Chavez L; Boop FA; Klimo P; Sabin ND; Ogg R; Mack SC; Freibaum BD; Kim HJ; Witt H; Jones DTW; Vo B; Gajjar A; Pounds S; Onar-Thomas A; Roussel MF; Zhang J; Taylor JP; Merchant TE; Grundy R; Tatevossian RG; Taylor MD; Pfister SM; Korshunov A; Kool M; Ellison DW
Acta Neuropathol; 2018 Aug; 136(2):211-226. PubMed ID: 29909548
[TBL] [Abstract][Full Text] [Related]
26. Intracranial ependymomas: molecular insights and translation to treatment.
Lester A; McDonald KL
Brain Pathol; 2020 Jan; 30(1):3-12. PubMed ID: 31433520
[TBL] [Abstract][Full Text] [Related]
27. Encouraging option of multi-staged gross total resection for a C11orf-RelA fusion-positive supratentorial anaplastic ependymoma.
Nakamura T; Fukuoka K; Ikeda J; Yoshitomi M; Udaka N; Tanoshima R; Tateishi K; Yamanaka S; Ichimura K; Yamamoto T
Brain Tumor Pathol; 2017 Oct; 34(4):160-164. PubMed ID: 28831588
[TBL] [Abstract][Full Text] [Related]
28. C11orf95-RELA fusion drives aberrant gene expression through the unique epigenetic regulation for ependymoma formation.
Ozawa T; Kaneko S; Szulzewsky F; Qiao Z; Takadera M; Narita Y; Kondo T; Holland EC; Hamamoto R; Ichimura K
Acta Neuropathol Commun; 2021 Mar; 9(1):36. PubMed ID: 33685520
[TBL] [Abstract][Full Text] [Related]
29. A non-hemispheric transtentorial ZFTA fusion-positive ependymoma in a 6-month-old boy.
Cardoni A; Barresi S; Piccirilli E; Alesi V; Miele E; Giovannoni I; Genovese S; Del Baldo G; Diomedi-Camassei F; Antonelli M; Giangaspero F; Puggioni C; Carai A; Colafati GS; Mastronuzzi A; Gessi M; Alaggio R; Rossi S
Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12886. PubMed ID: 36709981
[No Abstract] [Full Text] [Related]
30. C11orf95-RELA, YAP1-MAMLD1, and YAP1-FAM118B Fusion Negative Anaplastic Ependymoma with Lipogenic Differentiation.
Jha S; Mulgulwar PB; Sharma MC; Purkait S; Pattnaik A; Sable MN
Neurol India; 2023; 71(5):1011-1014. PubMed ID: 37929446
[TBL] [Abstract][Full Text] [Related]
31. Role of Immunohistochemistry in the Identification of Supratentorial C11ORF95-RELA Fused Ependymoma in Routine Neuropathology.
Gessi M; Giagnacovo M; Modena P; Elefante G; Gianno F; Buttarelli FR; Arcella A; Donofrio V; Diomedi Camassei F; Nozza P; Morra I; Massimino M; Pollo B; Giangaspero F; Antonelli M
Am J Surg Pathol; 2019 Jan; 43(1):56-63. PubMed ID: 29266023
[TBL] [Abstract][Full Text] [Related]
32. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
[TBL] [Abstract][Full Text] [Related]
33. Classification and neuroimaging of ependymal tumors.
Mu W; Dahmoush H
Front Pediatr; 2023; 11():1181211. PubMed ID: 37287627
[TBL] [Abstract][Full Text] [Related]
34. Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas.
Pohl LC; Leitheiser M; Obrecht D; Schweizer L; Wefers AK; Eckhardt A; Raffeld M; Sturm D; Pajtler KW; Rutkowski S; Fukuoka K; Ichimura K; Bockmayr M; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):24. PubMed ID: 38265522
[TBL] [Abstract][Full Text] [Related]
35. L1CAM Is Not a Reliable Diagnostic Biomarker for Distinguishing Supratentorial Ependymomas, ZFTA Fusion-Positive From Other Central Nervous System Tumors.
Aboubakr O; Metais A; Berthaud C; Gigant P; Mehdi L; Pucelle N; Lacombe J; Hasty L; Chrétien F; Lechapt E; Varlet P; Tauziède-Espariat A
J Neuropathol Exp Neurol; 2022 Jan; 81(1):82-85. PubMed ID: 35062030
[No Abstract] [Full Text] [Related]
36. Molecular characterization of histopathological ependymoma variants.
Neumann JE; Spohn M; Obrecht D; Mynarek M; Thomas C; Hasselblatt M; Dorostkar MM; Wefers AK; Frank S; Monoranu CM; Koch A; Witt H; Kool M; Pajtler KW; Rutkowski S; Glatzel M; Schüller U
Acta Neuropathol; 2020 Feb; 139(2):305-318. PubMed ID: 31679042
[TBL] [Abstract][Full Text] [Related]
37. Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study.
Chapman RJ; Ghasemi DR; Andreiuolo F; Zschernack V; Espariat AT; Buttarelli FR; Giangaspero F; Grill J; Haberler C; Paine SML; Scott I; Jacques TS; Sill M; Pfister S; Kilday JP; Leblond P; Massimino M; Witt H; Modena P; Varlet P; Pietsch T; Grundy RG; Pajtler KW; Ritzmann TA
Neuro Oncol; 2023 Oct; 25(10):1871-1882. PubMed ID: 36916248
[TBL] [Abstract][Full Text] [Related]
38. Phenotypic characterization with somatic genome editing and gene transfer reveals the diverse oncogenicity of ependymoma fusion genes.
Takadera M; Satomi K; Szulzewsky F; Cimino PJ; Holland EC; Yamamoto T; Ichimura K; Ozawa T
Acta Neuropathol Commun; 2020 Nov; 8(1):203. PubMed ID: 33228790
[TBL] [Abstract][Full Text] [Related]
39. Molecular subtyping of ependymoma and prognostic impact of Ki-67.
Lim KY; Lee K; Shim Y; Park JW; Kim H; Kang J; Won JK; Kim SK; Phi JH; Park CK; Chung CK; Yun H; Park SH
Brain Tumor Pathol; 2022 Jan; 39(1):1-13. PubMed ID: 34812989
[TBL] [Abstract][Full Text] [Related]
40. MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma.
Nowak J; Jünger ST; Huflage H; Seidel C; Hohm A; Vandergrift LA; von Hoff K; Rutkowski S; Pietsch T; Warmuth-Metz M
Clin Neuroradiol; 2019 Dec; 29(4):595-604. PubMed ID: 30027327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
